In another similar animal trial, the antioxidant treatment promoted the translocation of the transcription factor NRF2 to the nucleus and gene transcription of antioxidant enzymes, ultimately blocking epilepsy progression and producing neuroprotective effects (211). The gene discussed is NFE2L2; the disease is epilepsy.